Executive Team

Patrick Bennett

Patrick Bennett

Chief Executive Officer

Patrick Bennett

Patrick Bennett

Chief Executive Officer

Patrick has over 35 years’ experience in pharmaceutical analysis and laboratory management. From 1987 to 1993, he was a research scientist with the Bristol-Myers Company/Bristol-Myers Squibb. In 1993, he was the Lab Director at Advion (now IQVIA) in Ithaca, NY. In 1998, Patrick joined Tandem Labs (now LabCorp Drug Development) where he held the positions of Sr. Laboratory Director, General Manager and Vice President in a variety of roles at several of the Tandem Lab’s sites. His focus on method development processes and innovation resulted in the bridging of good science, speed, and customer focus. In 2010, Patrick joined Thermo Fisher Scientific as Strategic Marketing Director for Pharma and introduced the Q Exactive and Fusion mass spectrometers. Between 2014 and 2022, Patrick was Vice President of Strategy and Development at PPD Laboratories. He started the PPD biomarker lab, organized the Cell and Gene Therapy team and was responsible for the creation of PPD Labs in Suzhou, China. He is currently CEO of Alliance Pharma, Inc.

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.

JP Boutrand

JP Boutrand

Chief Operations Officer (COO)

JP Boutrand

JP Boutrand

Chief Operations Officer (COO)

JP comes to us with 25 years of contract research operational and commercial experience evaluating and developing drugs and medical technologies.

Most recently, JP served as Vice President at LabCorp Drug Development, Central Laboratories, Global Data Management and SaaS Solutions. In this global business unit leadership role, he designed and implemented operational process, productivity, and capacity improvements to improve client satisfaction, key performance indicators and financial results. Before LabCorp, JP was Vice President of global laboratories at North America Science Associates (NAMSA), where he drove efforts to accelerate market access for innovative medical technologies, acquisitions, and integration projects. In this position, JP handled strategy and operations in North America, Asia, and Europe. Prior to this role, JP served as Vice President of global sales at NAMSA and general manager, Scientific Director at Biomatech, a European CRO, offering clinical, regulatory consulting and laboratory research services.

JP holds a doctorate from the National Veterinary School of Lyon; a master’s in human biology and physiology from the University Claude Bernard in Lyon; degrees in global regulations of medical products from Denis Diderot Paris VII University; and a veterinary toxicology pathology certification from the National Veterinary School in Toulouse, France. He has completed business training programs at the Center for Creative Leadership and HEC, Paris.

Vito Saccente

Vito Saccente

Chief Commercial Officer (CCO)

Vito Saccente

Vito Saccente

Chief Commercial Officer (CCO)

Vito Saccente was appointed Chief Commercial Officer in July 2022 and brings over 25+ years of Sales Leadership experience in the Life Science, CRO industry including all aspects of nonclinical, clinical and CMC product development of vaccines, small molecules and large molecules.

Prior to joining Alliance Pharma, Vito was the Vice President of Sales, Vaccines and Biosciences for Q2 Solutions where he oversaw the commercial strategy and growth for vaccine, bioanalytical and ADME testing services. He also had active contributions to the corporate strategy for merger and acquisitions in his business unit.

Outside of work Vito enjoys time with family, golf and staying active.

Vito holds a Bachelor of Science degree, Business Administration from Monmouth College (now University) and has successfully completed management development programs from Harvard University and University of Southern California.

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer & EVP Scientific Partnership

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer & EVP Scientific Partnership

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Alliance Pharma. Dr. Zhao has over 25 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Alliance Pharma, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.

Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.

Glenn Weber

Glenn Weber

Chief Financial Officer (CFO)

Glenn Weber

Glenn Weber

Chief Financial Officer (CFO)

Glenn Weber joined Alliance Pharma in January 2022 as Chief Financial Officer. Glenn has over 35 years of experience in corporate finance in a variety of industries and roles. Glenn’s early career included financial analysis &corporate development work at tire industry companies Firestone and GenCorp followed by operational finance management at Cognis, a global chemical company once part of Henkel and now part of BASF.   From 2008-2014hewas CFO at Deufol North America (printing & contract packaging). Since 2014 Glenn has been CFO of private equity sponsored companies including CMG (2014-15 Interim – automotive OEM), Brook & Whittle (2016-18 including a successful exit - printing) and Squan (2019-21, telecom construction).  

Glenn earned his Bachelor’s degree in Accounting from the University of Akron in Akron, Ohio and earned his Master’s degree in Industrial Administration from Carnegie Mellon University’s Tepper School of Business in Pittsburgh, Pennsylvania.   Outside of work, he enjoys bicycling and world history.

Susan Woolley

Susan Woolley

Chief People Officer (CPO)

Susan Woolley

Susan Woolley

Chief People Officer (CPO)

Susan Woolley, CPO, is driving employee-centric initiatives that optimize Alliance Pharma’s success through development programs and engagement. She has 20 years of experience in change management, succession planning, talent development, coaching leaders, improving synergy, and effectiveness, and inspiring results across all levels of an organization.

Jing Tu

Jing Tu

Head of Corporate Development and Strategy

Jing Tu

Jing Tu

Head of Corporate Development and Strategy

Jing Tu is Head of Corporate Development and Strategy at Alliance Pharma (PA, USA). Jing has been working in the CRO and pharmaceutical industry since 2011. She started her career with Frontage Laboratories (PA, USA) in its biologics ligand binding services lab. As a Frontage scientist, she was then selected by Janssen R&D (formerly Centocor) to work within their ligand-binding laboratories in Spring House (PA, USA). In 2015, Jing joined PPD Laboratories’ (VA, USA) biomarker lab and started its biomarker ligand binding assay group. In 2018, Jing Joined the AbbVie (MA, USA) DMPK department and led its pre-clinical large molecule bioanalysis support. 

Jing has an M.B.A degree from Yale University (CT, USA) and graduated as the Class Marshall. She also has a medical degree from Norman Bethune School of Medicine Jilin University (Changchun, China).

Jing was a member of the Global CRO Council (GCC) from 2016 to 2018. She is also a current member of the organizing committee for Applied Pharmaceutical Analysis (APA), Bioanalysis Zoom Leader, and Expert Columnist. In 2018, she was named the winner of the Bioanalysis Rising Star Award.


Leadership Team

Feng (Frank) Li, Ph.D.

Feng (Frank) Li, Ph.D.

President & Founder

Feng (Frank) Li, Ph.D.

Feng (Frank) Li, Ph.D.

President & Founder

Feng (Frank) Li, Ph.D., is President of Alliance Pharma. He obtained his Ph.D. degree in Bioanalytical Chemistry jointly from Concordia University and the National Institute of Scientific Research (Canadian Doping Control Center) in Montreal, Canada. Subsequently, Dr. Li did his post-doctoral fellowship at the Biomedical Mass Spectrometry Facility at the Mayo Clinic in Rochester, Minnesota.

Furthermore, Dr. Li has an M.Sc. degree in Natural Product Chemistry and a B.S. in Pharmacy. He has held leadership roles in the Department of Drug Discovery Metabolism at Phoenix International Life Sciences, Inc., a major CRO at the time in Montreal, Canada, which was later acquired by MDS Pharma Services; in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline; and in the Drug Metabolism group in the Department of Drug Safety and Disposition at Cephalon, Inc. Dr. Li has extensive DMPK experience in discovery and developmental phases of drug development.

With more than 25 years in the pharmaceutical biotechnology, and CRO industry, he is well versed in bioanalytical techniques for both qualitative (drug metabolite identification) and quantitative (PK/TK) drug analysis, and has published numerous articles in the area of drug metabolite identification and quantitation.

Michael Zhang, Ph.D.

Michael Zhang, Ph.D.

Senior Vice President, Quality and Co-founder

Michael Zhang, Ph.D.

Michael Zhang, Ph.D.

Senior Vice President, Quality and Co-founder

Michael Zhang, Ph.D., serves as Vice President of Quality at Alliance Pharma. Prior to his current positon, Dr. Zhang was the Vice President of Operations. Dr. Zhang has extensive experience in Analytical Chemistry, Computer Science, and Quality and Regulatory Compliance. His expertise includes development and validation of LC-MS/MS methods for analyses of biological samples and pesticide/herbicide residue samples, FDA/EPA/OECD GLP compliance, quality management systems, analytical instrumentation, software development, information technology, and computerized systems validation.

Before joining Alliance, Dr. Zhang was an Associate Director at Keystone Analytical Laboratories (a subsidiary of former PharmaNet Development Group, Inc.). Dr. Zhang has developed numerous challenging LC-MS/MS methods for biological and agrochemical analyses, built up the IT infrastructure, and established GLP compliant laboratories and 21 CFR Part 11 compliant computerized systems at several companies.

Dr. Zhang has also worked as a software engineer at Motorola (Chicago, IL) and a Programmer Analyst at Affina (Peoria, IL). Dr. Zhang earned his Ph.D. degree in Analytical Chemistry and M.Sc. degree in Computer Science, both from the University of Missouri-Rolla (Rolla, MO). Dr. Zhang also holds an M.Sc. degree in Analytical Chemistry and a B.S. degree in Chemistry from the University of Science and Technology of China (Hefei, Anhui).

hs_jason2

Jason Wang

Site President

hs_jason2

Jason Wang

Site President

Jason obtained his Ph.D. in Environmental Science in 2007 from New Jersey Institute of Technology. After graduation, Jason worked in a few leading bioanalytical CROs on the east coast of New Jersey and Pennsylvania before he took over as a manager in TetraQ, University of Queensland, Australia in 2013. In 2020, Jason took another role as senior director of Bioanalysis at Q Square Solutions, Beijing China, prior to joining Alliance Pharma Australia in early 2022 as Site President.

Jason has over 15 years of experience in bioanalysis. From bench scientist to senior director, Jason acquired extensive knowledge and hands-on experience in bioanalytical method development, validation and sample analysis. He has expertise in both LC-MS/MS and Ligand binding assay, including immunogenicity. He is also very familiar with US FDA, EMA and NMPA regulations related to bioanalysis.

Jason also has over 8 years of management experience. During 7 years in TetraQ, Jason led the growth and expansion of TetraQ .


Scientific Team

greg_headshot2

Greg Kilby, Ph.D.

VP of Technology and Bioanalysis

greg_headshot2

Greg Kilby, Ph.D.

VP of Technology and Bioanalysis

Greg Kilby, Ph.D., is the VP of Technology and Bioanalysis and has over 2 decades of experience in leading scientists and in Separation and Mass Spectrometry analysis of biomolecules including protein characterization and proteomics.  Dr Kilby’s research interests can be summarized as applying advanced separations and mass spectrometry analytical platforms to answer challenging biological questions.

Prior to joining Alliance Pharma, Dr. Kilby was a Director, Biopharma R&D Analytical Sciences at AstraZeneca, leading a team supporting analytical development for multiple novel modality biopharmaceutical drug candidates - including ADC’s, bispecifics, fusion proteins, and other protein therapeutics - from clinical development through registration.

Previously, Dr. Kilby has had a broad range of experience at several fortune 500 pharmaceutical companies (Pfizer, GlaxoSmithKline and AstraZeneca) and instrument vendors (Agilent Technologies and Thermo Fisher Scientific) where he held a variety of positions with responsibilities ranging from CMC analytical development & characterization in biopharma R&D and business development, marketing, managing operations, laboratory facilities and life sciences applications development in Agilent, Thermo, and Protea Biosciences.

Hong Chen, Ph.D.

Hong Chen, Ph.D.

Sr. Scientific Director, Biopharmaceutical Services

Hong Chen, Ph.D.

Hong Chen, Ph.D.

Sr. Scientific Director, Biopharmaceutical Services

Hong Chen, Ph.D., serves as Scientific Director of the Biopharmaceutical Services department at Alliance Pharma. Hong has more than a decade of experience in immuno-assay development, validation and sample analysis in support of multiple clinical and preclinical studies.

Prior to joining Alliance, Dr. Chen was a Sr. Scientist at Reaction Biology Corporation and a Principal Scientist at GlaxoSmithKline. Dr. Chen earned her doctorate degree in Molecular and Cellular Biology from Temple University in Philadelphia, Pennsylvania. Subsequently, she did a postdoctoral fellowship at the University of Pennsylvania, Perelman School of Medicine in the laboratory of Dr. Mark Kahn.

Dr. Chen has published numerous scientific papers in the field of immunology, virology, molecular biology, and vascular biology in multiple scientific journals including Gene and Development, Proc. Natl. Acad. Sci. USA, Blood, Journal of Biologic Chemistry, and Molecular Cell Biology.

hs_yong

Yong Lin

Director, Biopharmaceutical Services

hs_yong

Yong Lin

Director, Biopharmaceutical Services

Yong Lin has served as a scientist and significant contributor to the Biopharmaceutical Services department at Alliance Pharma since 2010, responsible for method development and validation to support pharmacokinetic and immunogenicity studies. As a Principal Investigator at Alliance, Yong leads various projects and plays a key role interacting with clients, as well as designing and executing experiments.

Yong has more than 20 years of experience in the pharmaceutical industry. Prior to joining Alliance Pharma, he spent time at Bausch & Lomb, MDS Pharma, and IBEX Pharmaceuticals supporting various stages of Research and Development by executing cell-based and immune-assays using various platforms.

Yong earned a Masters in Veterinary Medicine from South China Agricultural University, as well as a Masters in Cell Biology from McGill University in Canada. Throughout his career, Yong has published a number of research articles in peer reviewed journals, and co-authored various patents.

hs_aihua

Aihua Liu, Ph.D.

Director, Bioanalysis

hs_aihua

Aihua Liu, Ph.D.

Director, Bioanalysis

Aihua Liu, Ph.D., is the Director of Bioanalysis in Alliance Pharma. She holds a Ph.D. in Analytical Chemistry, an M.S. in Pharmaceutical Chemistry, and a B.S. in Pharmacy. She has five years of postdoctoral training in Biochemistry. Prior to joining Alliance Pharma, she was the Director of R&D and Chromatography in Dyad Labs after serving as the Team Lead of the bioanalytical method development group at Covance in Salt Lake City.


Dr. Liu has more than 15 years of experience in bioanalysis. Her research interests focus on novel analytical method development/validation and its sample analysis in bioanalysis of small molecules, oligonucleotides, ADC, lipids, DBS et al. In the previous company, Dr. Liu has successfully established a chromatography lab and team, which significantly increased the company’s revenue and profit.


Dr. Liu has authored more than 65 peer-reviewed publications, abstracts, conference posters/oral presentations and book chapters in the areas of analytical chemistry and herbal medicine. She is an active member of the American Association of Pharmaceutical Scientists (AAPS), the American Society of Mass Spectrometry (ASMS), the American Organization of Analytical Chemists (AOAC), and the International Conference on the Science of Botanicals (ICSB).